Vasopharm seeks brain injury drug partner on positive Phase II
This article was originally published in Scrip
Executive Summary
German firm, Vasopharm, said it is seeking a strategic partner to accelerate the further development of VAS203 for traumatic brain injury (TBI), after reporting that Phase IIa results for the drug candidate had 'exceeded expectations'.